Related Experiment Videos
[Vasodilatory septic shock refractory to catecholamines: is there a role for terlipressin?]
J L Fellahi1, P Bénard, G Daccache
1Service d'anesthésie-réanimation, centre hospitalier privé Saint-Martin, 18, rue des Roquemonts, 14050 Caen, France. jean-luc.fellahi@stmartin-caen.gsante.fr
Abstract:
We report two patients in vasodilatory septic shock refractory to catecholamines in which a continuous infusion of terlipressin was associated with a dramatic increase in systemic arterial blood pressure and short-term survival. Low doses of terlipressin were sufficient in both cases (0.01-0.0 mg h(-1)) to restore blood pressure by increase of systemic vascular resistances. The haemodynamic response was immediate, long-acting, dose-dependent and reversible in a few hours when the drug administration was stopped. A further increase in terlipressin dose regimen markedly decreased cardiac performance. Terlipressin simultaneously induced vasoconstriction within the cutaneous vascular territory, leading to local skin necrosis. The splanchnic vascular territory seemed to be constricted in the same way. Further studies are needed to better understand and precise the role of terlipressin in the treatment of vasodilatory septic shock refractory to catecholamines.
Related Concept Videos
Cardiopulmonary Resuscitation IV: Pharmacological Management
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure V: Medical Management
Heart Failure VI: Adjunct Therapies
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...